AU2001264736A1 - Gabapentin analogues for sleep disorders - Google Patents
Gabapentin analogues for sleep disordersInfo
- Publication number
- AU2001264736A1 AU2001264736A1 AU2001264736A AU2001264736A AU2001264736A1 AU 2001264736 A1 AU2001264736 A1 AU 2001264736A1 AU 2001264736 A AU2001264736 A AU 2001264736A AU 2001264736 A AU2001264736 A AU 2001264736A AU 2001264736 A1 AU2001264736 A1 AU 2001264736A1
- Authority
- AU
- Australia
- Prior art keywords
- aminomethyl
- acetic acid
- cyclopentyl
- cyclobutyl
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Description
GABAPENTLN ANALOGUES FOR SLEEP DISORDERS
BACKGROUND OF THE INVENTION
Compounds of formula
^N-C^-C-C^-COORT
(CH2>n
wherein Ri is hydrogen or a lower alkyl radical and n is 4, 5, or 6 are known in
United States Patent Number 4,024,175 and its divisional United States Patent Number 4,087,544. The uses disclosed are: protective effect against cramp induced by tbiosemicarbazide; protective action against cardiazole cramp; the cerebral diseases, epilepsy, faintness attacks, hypokinesia, and cranial traumas; and improvement in cerebral functions. The compounds are useful in geriatric patients. The patents are hereby incorporated by reference.
United States Patent Application 09/485,382 filed February 8, 2000, covers compounds of formulas 1 and 1A below. The application discloses various utilities for the compounds. This is incorporated by reference. Compounds of Formula I
wherein Ri is hydrogen or lower alkyl and n is an integer of from 4 to 6, and the pharmaceutically acceptable salts thereof and compounds of Formula II R4 R3
I I
H2NCH— C— CH COOH II
R2
hydrogen, methyl, or carboxyl; or an individual enantiomeric isomer thereof; or a pharmaceutically acceptable salt thereof, are useful in the treatment of insomnia (United States Patent Application 60/092166 filed July 9, 1998, which is incorporated here by reference).
SUMMARY OF THE INVENTION
The instant invention is a method of treating insomnia, that is, difficulty in sleeping or disturbed sleep patterns which leave the perception of insufficient sleep. Insomnia is a common symptom which may be due to several emotional and physical disorders (The Merck Manual, 16 ed., pp 1445-6). The benefit of using compounds of the invention to treat insomnia is that they are not addictive. Additionally, they have a half-life in the body that is suitable to work during the evening and subsequently clear the body by morning to allow for easy arousal. The compounds can be combined with other agents to enhance the sleep inducing effects. Such agents include melatonin, tryptophan, valerian, passiflora, antihistamines such as diphenydramine hydrochloride or doxylamine succinate, benzodiazepines, and nonbenzodiazepines hypnotics.
Additional advantages of using the compounds of formula 1 and 1 A in the present invention include the relatively nontoxic nature of the compounds, the ease of preparation, the fact that the compounds are well-tolerated, and the ease of rV administration of the drugs. The subjects treated with the method of the present invention are mammals, including humans.
The compounds useful in the practice of the invention are those of formulas 1 and 1A
1 1A wherein R to R*4 are as defined below.
The compounds of the invention and their pharmaceutically acceptable salts and the prodrugs of the compounds are useful in the treatment of insomnia and sleeplessness.
DETAILED DESCRIPTION OF THE INVENTION
The compounds useful in the instant invention and their pharmaceutically acceptable salts are as defined by formulas 1 and 1 A
1A or a pharmaceutically acceptable salt thereof wherein:
R is hydrogen or a lower alkyl;
Ri to Rl4 are each independently selected from hydrogen, straight or branched alkyl of from 1 to 6 carbons, phenyl, benzyl, fluorine, chlorine, bromine, hydroxy, hydroxymethyl, amino, aminomethyl, trifluoromethyl, -CO H, -CO2Rl 5, -CH2CO2H, -CH2CO2R! 5, -OR15 wherein Rl 5 is a straight or branched alkyl of from 1 to 6 carbons, phenyl, or benzyl, and R1 to R^ are not simultaneously hydrogen.
Preferred compounds of the invention are those of Formula I wherein R1 to Rl4 are selected from hydrogen, methyl, ethyl, propyl, isopropyl, butyl straight or branched, phenyl, or benzyl.
More preferred compounds are those of Formula I wherein R1 to R1^ are selected from hydrogen, methyl, ethyl, or benzyl.
The most preferred compounds are selected from:
(1 α,3α,4α)-(l-Aminomethyl-3,4-dimethyl-cyclopentyl)-acetic acid;
(lα,3α,4α)-(l-Aminomethyl-3,4-diethyl-cyclopentyl)-acetic acid;
(l ,3α,4 )-(l-Aminomethyl-3,4-diisopropyl-cyclopentyl)-acetic acid; [ 1 S-( 1 ,3 α,4α)] -( 1 -Aminomethyl-3 -ethyl-4-methyl-cyclopentyl)-acetic acid;
[lR-(l ,3α,4 )]-(l-Aminomethyl-3-ethyl-4-methyl-cyclopentyl)-acetic acid;
[lS-(lα,3 α,4α)] -(1 -Aminomethyl-3 -isopropyl-4-methyl-cyclopentyι)- acetic acid;
[ 1 R-(l α,3 ,4α)]-(l -Aminomethyl-3-isopropyl-4-methyl-cyclopentyl)- acetic acid;
[lS-(lα,3α,4α)]-(l-Aminomethyl-3-ethyl-4-isopropyl-cyclopentyl)-acetic acid; [lR-(lα,3 α,4α)] -(1 -Aminomethyl-3 -ethyl-4-isopropyl-cyclopentyl)-acetic acid;
[lS-(lα,3 ,4α)]-(l-Aminomethyl-3-tert-butyl-4-methyl-cyclopentyl)- acetic acid;
[lR-(lα,3 ,4α)]-(l-Aminomethyl-3-tert-butyl-4-methyl-cyclopentyl)- acetic acid;
[1 S-(l ,3 α,4α)]-(l -Aminomethyl-3-tert-butyl-4-ethyl-cyclopentyl)-acetic acid;
[ 1 R-( 1 α,3 α,4α)]-(l -Aminomethyl-3 -tert-butyl-4-ethyl-cyclopentyl)-acetic acid;
[lS-(lα,3α,4α)]-(l-Aminomethyl-3-tert-butyl-4-isopropyl-cyclopentyl)- acetic acid;
[lR-(lα,3α,4α)]-(l-Aminomethyl-3-tert-butyl-4-isopropyl-cyclopentyl)- acetic acid; (1 α,3α,4α)-(l -Aminomethyl-3 ,4-di-tert-butyl-cyclopentyl)-acetic acid;
[1 S-(l α,3α,4 )]-(l -Aminomethyl-3-methyl-4-phenyl-cyclopentyl)-acetic acid;
[ 1 R-( 1 α,3 α,4α)] -(1 -Aminomethyl-3 -methyl-4-phenyl-cyclopentyl)-acetic acid; [lS-(lα,3 ,4α)]-(l-Aminomethyl-3-benzyl-4-methyl-cyclopentyl)-acetic acid;
[lR-(lα,3α,4α)]-(l-Aminomethyl-3-benzyl-4-methyl-cyclopentyl)-acetic acid;
(1 S-cis)-(l -Aminomethyl-3 -methyl-cyclopentyl)-acetic acid; (1 S-cis)-(l -Aminomethyl-3-ethyl-cyclopentyl)-acetic acid; (1 S-cis)-(l-Aminomethyl-3-isopropyl-cyclopentyl)-acetic acid; (1 S-cis)-(l-Aminomethyl-3-tert-butyl-cyclopentyl)-acetic acid; (1 S-cis)-(l-Aminomethyl-3-phenyl-cyclopentyl)-acetic acid; (1 S-cis)-(l -Aminomethyl-3-benzyl-cyclopentyl)-acetic acid; (lR-cis)-(l -Aminomethyl-3-methyl-cyclopentyl)-acetic acid; (lR-cis)-(l -Aminomethyl-3-ethyl-cyclopentyl)-acetic acid; (1 R-cis)-(l -Aminomethyl-3 -isopropyl-cyclopentyl)-acetic acid; (1 R-cis)-(l -Aminomethyl-3-tert-butyl-cyclopentyl)-acetic acid; ( 1 R-cis)-( 1 -Aminomethyl-3 -phenyl-cyclopentyl)-acetic acid; (lR-cis)-(l -Aminomethyl-3-benzyl-cyclopentyl)-acetic acid; (S)-(l -Aminomethyl-3, 3 -dimethyl-cyclopentyl)-acetic acid; (S)-( 1 -Aminomethyl-3 ,3 -diethyl-cyclopentyl)-acetic acid; (1 -Aminomethyl-3,3,4,4-tetramethyl-cyclopentyl)-acetic acid; (1 -Aminomethyl-3, 3, 4,4-tetraethyl-cyclopentyl)-acetic acid; ( 1 α,3 β,4β)-( 1 -Aminomethyl-3 ,4-dimethyl-cyclopentyl)-acetic acid; ( 1 ,3 β,4β)-( 1 -Aminomethyl-3 ,4-diethyl-cyclopentyl)-acetic acid;
( 1 α,3 β,4β)-( 1 -Aminomethyl-3 ,4-diisopropyl-cyclopentyl)-acetic acid; [lR-(lα,3β,4β)]-(l-Aminomethyl-3-ethyl-4-methyl-cyclopentyl)-acetic acid;
[1 S-(l α,3β,4β)]-(l -Aminomethyl-3-ethyl-4-methyl-cyclopentyl)-acetic acid;
[1R-(1 ,3β,4β)]-(l -Aminomethyl-3-isopropyl-4-methyl-cyclopentyl)- acetic acid;
[lS-(lα,3β,4β)]-(l-Aminomethyl-3-isopropyl-4-methyl-cyclopentyl)- acetic acid; [lR-(lα,3β,4β)]-(l-Aminomethyl-3-ethyl-4-isopropyl-cyclopentyl)-acetic acid;
[ 1 S-( 1 ,3 β,4β)] -( 1 - Aminomethyl-3-ethyl-4-isopropyl-cyclopentyl)-acetic acid;
[lR-(lα,3β,4β)]-(l-Aminomethyl-3-tert-butyl-4-methyl-cyclopentyl)- acetic acid;
[lS-(lα,3β,4β)]-(l-Aminomethyl-3-tert-butyl-4-methyl-cyclopentyl)- acetic acid;
[lR-(l ,3β,4β)]-(l-Ammomethyl-3-tert-butyl-4-ethyl-cyclopentyl)-acetic acid; [lS-(lα,3β,4β)]-(l-Aminomethyl-3-tert-butyl-4-ethyl-cyclopentyl)-acetic acid;
[lR-(lα,3β,4β)]-(l-Aminomethyl-3-tert-butyl-4-isopropyl-cyclopentyl)- acetic acid;
[lS-(lα,3β,4β)]-(l-Aminomethyl-3-tert-butyl-4-isopropyl-cyclopentyl)- acetic acid;
(lα,3β,4β)-(l-Aminomethyl-3,4-di-tert-butyl-cyclopentyl)-acetic acid; [ 1 R-( 1 ,3 β,4β)] -( 1 -Aminomethyl-3 -methyl-4-phenyl-cyclopentyl)-acetic acid;
[1 S-(l α,3β,4β)]-(l -Aminomethyl-3-methyl-4-phenyl-cyclopentyl)-acetic acid;
[lR-(lα,3β,4β)]-(l-Aminomethyl-3-benzyl-4-methyl-cyclopentyl)-acetic acid;
[ 1 S-(l ,3 β,4β)] -( 1 -Aminomethyl-3 -benzyl-4-methyl-cyclopentyι)-acetic acid;
(lR-trans)-(l-Aminomethyl-3-methyl-cyclopentyl)-acetic acid; (lR-trans)-(l-Aminomethyl-3-ethyl-cyclopentyl)-acetic acid; (1 R-trans)-(l -Aminomethyl-3 -isopropyl-cyclopentyl)-acetic acid; (lR-trans)-(l -Aminomethyl-3-tert-butyl-cyclopentyl)-acetic acid; ( 1 R-trans)-( 1 -Aminomethyl-3 -phenyl-cyclopentyl)-acetic acid; ( 1 R-trans)-( 1 -Aminomethyl-3 -benzyl-cyclopentyl)-acetic acid; (1 S-trans)-(l -Aminomethyl-3-methyl-cyclopentyl)-acetic acid; (1 S-trans)-(l -Aminomethyl-3-ethyl-cyclopentyl)-acetic acid; (1 S-trans)-(l -Aminomethyl-3 -isopropyl-cyclopentyl)-acetic acid; (1 S-trans)-(l -Aminomethyl-3-tert-butyl-cyclopentyl)-acetic acid; (1 S-trans)-(l -Aminomethyl-3-phenyl-cyclopentyl)-acetic acid; (1 S-trans)-(l -Aminomethyl-3 -benzyl-cyclopentyl)-acetic acid; (R)-(l-Aminomethyl-3,3-dimethyl-cyclopentyl)-acetic acid; (R)-( 1 -Aminomethyl-3 ,3 -diethyl-cyclopentyl)-acetic acid; cis-(l-Aminomethyl-3-methyl-cyclobutyl)-acetic acid; cis-(l-Aminomethyl-3-ethyl-cyclobutyl)-acetic acid; cis-(l-Aminomethyl-3-isopropyl-cyclobutyl)-acetic acid; cis-(l -Aminomethyl-3 -tert-butyl-cyclobutyl)-acetic acid; cis-(l-Aminomethyl-3-ρhenyl-cyclobutyl)-acetic acid; cis-(l -Aminomethyl-3-benzyl-cyclobutyl)-acetic acid; trans-(l -Aminomethyl-3-methyl-cyclobutyl)-acetic acid; trans-(l -Aminomethyl-3 -ethyl-cyclobutyl)-acetic acid; trans-( 1 -Aminomethyl-3 -isopropyl-cyclobutyl)-acetic acid; trans-(l-Aminomethyl-3-tert-butyl-cyclobutyl)-acetic acid; trans-(l -Aminomethyl-3 -phenyl-cyclobutyl)-acetic acid; trans-(l -Aminomethyl-3 -benzyl-cyclobutyl)-acetic acid; cis-(l -Aminomethyl-3-ethyl-3-methyl-cyclobutyl)-acetic acid;
cis-(l -Aminomethyl-3 -isopropyl-3 -methyl-cyclobutyl)-acetic acid; cis-(l -Aminomethyl-3 -tert-butyl-3 -methyl-cyclobutyl)-acetic acid; cis-(l -Aminomethyl-3 -methyl-3-phenyl-cyclobutyl)-acetic acid; cis-(l -Aminomethyl-3-benzyl-3-methyl-cyclobutyl)-acetic acid; frans-(l-Aminomethyl-3-ethyl-3-methyl-cyclobutyl)-acetic acid; trans-( 1 -Aminomethyl-3 -isopropyl-3 -methyl-cyclobutyl)-acetic acid; trans-(l -Aminomethyl-3-tert-butyl-3-methyl-cyclobutyl)-acetic acid; trans-(l -Aminomethyl-3-methyl-3-phenyl-cyclobutyl)-acetic acid; trans-( 1 -Aminomethyl-3 -benzyl-3 -methyl-cyclobutyl)-acetic acid; cis-(l -Aminomethyl-3 -ethyl-3 -isopropyl-cyclobutyl)-acetic acid; cis-(l -Aminomethyl-3 -tert-butyl-3 -ethyl-cyclobutyl)-acetic acid; cis-( 1 -Aminomethyl-3 -ethyl-3 -phenyl-cyclobutyl)-acetic acid; cis-( 1 -Aminomethyl-3 -benzyl-3 -ethyl-cyclobutyl)-acetic acid; trans-( 1 -Aminomethyl-3 -ethyl-3 -isopropyl-cyclobutyl)-acetic acid; trans-(l-Aminomethyl-3-tert-butyl-3-ethyl-cyclobutyl)-acetic acid; trans-( 1 -Aminomethyl-3 -ethyl-3 -phenyl-cyclobutyl)-acetic acid; trans-( 1 -Aminomethyl-3 -benzyl-3 -ethyl-cyclobutyl)-acetic acid; cis-( 1 -Aminomethyl-3 -tert-butyl-3 -isopropyl-cyclobutyl)-acetic acid; cis-(l-Aminomethyl-3-isopropyl-3-phenyl-cyclobutyl)-acetic acid; trans-(l-Aminomethyl-3-benzyl-3-isopropyl-cyclobutyl)-acetic acid; cis-(l-Aminomethyl-3-tert-butyl-3-phenyl-cyclobutyl)-acetic acid; trans-(l-Aminomethyl-3-benzyl-3-tert-butyl-cyclobutyl)-acetic acid; trans-( 1 -Aminomethyl-3 -tert-butyl-3 -isopropyl-cyclobutyl)-acetic acid; trans-( 1 -Aminomethyl-3 -isopropyl-3 -phenyl-cyclobutyl)-acetic acid; cis-(l-Aminomethyl-3-benzyl-3-isopropyl-cyclobutyl)-acetic acid; trans-(l -Aminomethyl-3-tert-butyl-3-phenyl-cyclobutyl)-acetic acid; cis-(l -Aminomethyl-3 -benzyl-3 -tert-butyl-cyclobutyl)-acetic acid;
( 1 -Aminomethyl-3 ,3 -dimethyl-cyclobutyl)-acetic acid;
(l-Aminomethyl-3,3-diethyl-cyclobutyl)-acetic acid; (l-Aminomethyl-3,3-diisopropyl-cyclobutyl)-acetic acid;
(l-Aminomethyl-3,3-di-tert-butyl-cyclobutyl)-acetic acid;
(1 -Aminomethyl-3 ,3-diphenyl-cyclobutyi)-acetic acid;
1 -Aminomethyl-3 ,3 -dibenzyl-cyclobutyl)-acetic acid; 1 -Aminomethyl-2,2,4,4-tetramethyl-cyclobutyl)-acetic acid; 1 -Aminomethyl-2,2,3 ,3 ,4,4-hexamethyl-cyclobutyl)-acetic acid; (R)-(l -Aminomethyl-2,2-dimethyl-cyclobutyl)-acetic acid; S)-(l -Aminomethyl-2,2-dimethyl-cyclobutyl)-acetic acid; 1 R-cis)-( 1 -Aminomethyl-2-methyl-cyclobutyl)-acetic acid; 1 R-( 1 α,2α,3 )]-( 1 - Aminomethyl-2,3 -dimethyl-cyclobutyl)-acetic acid; 1 α,2 ,4α)-(l -Aminomethyl-2,4-dimethyl-cyclobutyl)-acetic acid; lR-(lα,2α,3β)]-(l-Aminomethyl-2,3-dimethyl-cyclobutyl)-acetic acid; 1 α,2α,4β)-(l -Aminomethyl-2,4-dimethyl-cyclobutyl)-acetic acid; 1 S-trans)-(l -Aminomethyl-2-methyl-cyclobutyl)-acetic acid; lS-(lα,2β,3β)]-(l-Aminomethyl-2,3-dimethyl-cyclobutyl)-acetic acid; lα,2β,4β)- (l-Aminomethyl-2,4-dimethyl-cyclobutyl)-acetic acid; lS-(lα,2β,3α)]-(l-Aminomethyl-2,3-dimethyl-cyclobutyl)-acetic acid; 1 ,2β,4α)-(l -Aminomethyl-2,4-dimethyl-cyclobutyl)-acetic acid; 1 R-trans)-( 1 - Aminomethyl-2-methyl-cyclobutyl)-acetic acid; lR-(lα,2β,3β)]-(l-Aminomethyl-2,3-dimethyl-cyclobuιyl)-acetic acid; lR-(lα,2β,4β)]-(l-Aminomethyl-2-ethyl-4-methyl-cyclobutyl)-acetic acid; lR-(lα,2β,3α)]-(l-Aminomethyl-2,3-dimethyl-cyclobutyl)-acetic acid; 1 α,2β,4α)-(l -Aminomethyl-2,4-dimethyl-cyclobutyl)-acetic acid; 1 S-cis)-(l-Aminomethyl-2-methyl-cyclobutyl)-acetic acid; 1 S-(l ,2α,3 )]-(l -Aminomethyl-2,3-dimethyl-cyclobutyl)-acetic acid; 1 S-(l ,2α,3α)]-(l -Aminomethyl-2,4-dimethyl-cyclobutyl)-acetic acid; lS-(l ,2β,3 )]-(l-Aminomethyl-2,3-dimethyl-cyclobutyl)-acetic acid; 1 ,2α,4β)-(l -Aminomethyl-2,4-dimethyl-cyclobutyl)-acetic acid; 3S, 4S)-(1 -Aminomethyl-3 ,4-dimethyl-cyclopentyl)-acetic acid; 3R, 4R)-(1 - Aminomethyl-3, 4-dimethyl-cyclopentyl)-acetic acid; 3R, 4R)-(1 -Aminomethyl-3 ,4-diethyl-cyclopentyl)-acetic acid; 3S, 4S)-(1 -Aminomethyl-3,4-diisopropyl-cyclopentyl)-acetic acid;
(3R, 4R)-(1 -Aminomethyl-3 ,4-diisopropyl-cyclopentyl)-acetic acid;
(3S, 4S)-(l-Aminomethyl-3,4-di-tert-butyl-cyclopentyl)-acetic acid;
(3R, 4R)-(l-Aminomethyl-3,4-di-tert-butyl-cyclopentyl)-acetic acid;
(3S, 4S)-(l-Aminomethyl-3,4-diphenyl-cyclopentyl)-acetic acid; (3R, 4R)-(1 -Aminomethyl-3 ,4-diphenyl-cyclopentyl)-acetic acid;
(3S, 4S)-(l-Aminomethyl-3,4-dibenzyl-cyclopentyl)-acetic acid;
(3R, 4R)-(1 -Aminomethyl-3 ,4-dibenzyl-cyclopentyl)-acetic acid;
[lS-(l ,3α,4β)]-(l-Aminomethyl-3-methyl-4-ethyl-cyclopentyl)-acetic acid; [lR-(l ,3β,4α)]-(l-Aminomethyl-3-methyl-4-ethyl-cyclopentyl)-acetic acid;
[lR-(l ,3 ,4β)]-(l-Aminomethyl-3-methyl-4-ethyl-cyclopentyl)-acetic acid;
[lS-(l ,3β,4 )]-(l-Aminomethyl-3-methyl-4-ethyl-cyclopentyl)-acetic acid;
[1 S-(l α,3 ,4β)]-(l -Aminomethyl-3-methyl-4-isopropyl-cyclopentyl)- acetic acid;
[ 1 R-( 1 α,3 β,4α)] -( 1 -Aminomethyl-3 -methyl-4-isopropyl-cyclopentyl)- acetic acid; [1R-(1 α,3α,4β)]-(l -Aminomethyl-3-methyl-4-isopropyl-cyclopentyl)- acetic acid;
[1 S-(l ,3β,4 )]-(l -Aminomethyl-3-methyl-4-isopropyl-cyclopentyl)- acetic acid;
[1 S-(l α,3α,4β)]-(l -Aminomethyl-3-methyl-4-tert-butyl-cyclopentyl)- acetic acid;
[lR-(lα,3β,4α)]-(l-Aminomethyl-3-methyl-4-tert-butyl-cyclopentyl)- acetic acid;
[lR-(lα,3α,4β)]-(l-Aminomethyl-3-methyl-4-tert-butyl-cyclopentyl)- acetic acid;
[lS-(l ,3β,4β)]-(l-Ammomethyl-3-methyl-4-tert-butyl-cyclopentyl)- acetic acid;
[lS-(l 53α,4β)]-(l-Aminomethyl-3-methyl-4-phenyl-cyclopentyl)-acetic acid; [ 1 R-( 1 α,3 β,4α)] -(1 -Aminomethyl-3 -methyl-4-phenyl-cyclopentyl)-acetic acid;
[lR-(lα,3α,4β)]-(l-Aminomethyl-3-methyl-4-phenyl-cyclopentyl)-acetic acid;
[ 1 S-( 1 ,3 β,4α)] -(1 -Aminomethyl-3 -methyl-4-phenyl-cyclopentyl)-acetic acid;
[ 1 S-(l ,3 α,4β)] -( 1 -Aminomethyl-3 -benzyl-4-methyl-cyclopentyl)-acetic acid;
[ 1 R-(l α,3 β,4α)] -( 1 -Aminomethyl-3 -benzyl-4-methyl-cyclopentyl)-acetic acid; [lR-(lα,3 ,4β)]-(l-Aminomethyl-3-benzyl-4-methyl-cyclopentyl)-acetic acid;
[lS-(lα,3β,4 )]-(l-Aminomethyl-3-benzyl-4-methyl-cyclopentyl)-acetic acid;
[lS-(lα,3 ,4β)]-(l-Aminomethyl-3-ethyl-4-isopropyl-cycloperityl)-acetic acid;
[lR-(lα,3β,4α)]-(l-Aminomethyl-3-ethyl-4-isopropyl-cyclopentyl)-acetic acid;
[lR-(l ,3 ,4β)]-(l-Aminomethyl-3-ethyl-4-isopropyl-cyclopentyl)-acetic acid; [lS-(l ,3β,4α)]-(l-Aminomethyl-3-ethyl-4-isopropyl-cyclopentyl)-acetic acid;
[lS-(l ,3α,4β)]-(l-Aminomethyl-3-tert-butyl-4-ethyl-cyclopentyl)-acetic acid;
[lR-(lα,3β,4α)]-(l-Aminomethyl-3-tert-butyl-4-ethyl-cyclopentyl)-acetic acid;
[1 R-(l α,3 ,4β)]-(l -Aminomethyl-3-tert-butyl-4-ethyl-cyclopentyl)-acetic acid;
[lS-(lα,3β,4α)]-(l-Aminomethyl-3-tert-butyl-4-ethyl-cyclopentyl)-acetic acid; [1 S-(l α,3α,4β)]-(l-Aminomethyl-3-ethyl-4-phenyl-cyclopentyl)-acetic acid;
[lR-(lα,3β,4α)]-(l-Aminomethyl-3-ethyl-4-phenyl-cyclopentyl)-acetic acid;
[ 1 R-( 1 α,3 α,4β)] -(1 -Aminomethyl-3 -ethyl-4-phenyl-cyclopentyl)-acetic acid;
[1 S-(l α,3β,4α)]-(l-Aminomethyl-3-ethyl-4-phenyl-cyclopentyl)-acetic . acid;
[lS-(l ,3 ,4β)]-(l-Aminomethyl-3-benzyl-4-ethyl-cyclopentyl)-acetic acid; [1 R-(l α,3 β,4α)]-(l -Aminomethyl-3-benzyl-4-ethyl-cyclopentyl)-acetic acid;
[lR-(lα,3α,4β)]-(l-Aminomethyl-3-benzyl-4-ethyl-cyclopentyl)-acetic acid;
[lS-(lα,3β,4 )]-(l-Aminomethyl-3-benzyl-4-ethyl-cyclopentyl)-acetic acid;
[lS-(lα,3α,4β)]-(l-Aminomethyl-3-tert-butyl-4-isopropyl-cyclopentyl)- acetic acid;
[lR-(lα,3β,4α)]-(l-Aminomethyl-3-tert-butyl-4-isopropyl-cyclopentyl)- acetic acid; [lR-(l ,3α,4β)]-(l-Aminomethyl-3-tert-butyl-4-isopropyl-cyclopentyl)- acetic acid;
[ 1 S-( 1 α,3 β,4α)] -( 1 -Aminomethyl-3 -tert-butyl-4-isopropyl-cyclopentyi)- acetic acid;
[lS-(lα,3α,4β)]-(l-Aminomethyl-3-isopropyl-4-phenyl-cyclopentyl)- acetic acid;
[lR-(lα,3β,4α)]-(l-Aminomethyl-3-isopropyl-4-phenyl-cyclopentyl)- acetic acid;
[lR-(lα,3 ,4β)]-(l-Aminomethyl-3-isopropyl-4-phenyl-cyclopentyl)- acetic acid; [ 1 S-(l α,3 β,4α)] -( 1 -Aminomethyl-3 -isopropyl-4-phenyl-cyclopentyl)- acetic acid;
[ 1 S-(l α,3 α,4β)] -(1 -Aminomethyl-3 -benzyl-4-isopropyl-cyclopentyI)- acetic acid;
[lR-(lα,3β,4α)]-(l-Aminomethyl-3-benzyl-4-isopropyl-cyclopentyl)- acetic acid;
[lR-(lα,3 ,4β)]-(l-Aminomethyl-3-benzyl-4-isopropyl-cyclopentyl)- acetic acid;
[lS-(lα,3 β,4α)] -(1 -Aminomethyl-3 -benzyl-4-isopropyl-cyclopentyl)- acetic acid; [lS-(lα,3α,4β)]-(l-Aminomethyl-3-tert-buιyl-4-phenyl-cyclopentyl)- acetic acid;
[ 1 R-( 1 α,3 β,4α) ] -(1 -Aminomethyl-3 -tert-butyl-4-phenyl-cyclopentyl)- acetic acid;
[lR-(l ,3α,4β)]-(l-Aminomethyl-3-tert-butyl-4-phenyl-cyclopentyl)- acetic acid;
[lS-(lα,3β,4α)]-(l-Aminomethyl-3-tert-butyl-4-phenyl-cyclopentyl)- acetic acid;
[ 1 R-( 1 α,3 α,4β)] -(1 -Aminomethyl-3 -benzyl-4-tert-butyl-cyclopentyl)- acetic acid; [lS-(lα,3β,4 )]-(l -Aminomethyl-3 -benzyl-4-tert-butyl-cyclopentyl)-acetic acid;
[ 1 S-( 1 α,3 α,4β)] -( 1 -Aminomethyl-3 -benzyl-4-tert-butyl-cyclopentyl)-acetic acid;
[ 1 R-( 1 α,3 β,4 )] -(1 -Aminomethyl-3 -benzyl-4-tert-butyl-cyclopentyl)- acetic acid;
1 S-( 1 ,3 α,4β)] -(1 -Aminomethyl-3 -benzyl-4-phenyl-cyclopentyl)-acetic acid; lR-(lα,3β,4α)]-(l-Aminomethyl-3-benzyl-4-phenyl-cyclopentyl)-acetic acid; lR-(lα,3α,4β)]-(l-Aminomethyl-3-benzyl-4-phenyl-cyclopentyl)-acetic acid;
1 S-( 1 α,3 β,4α)] -(1 -Aminomethyl-3 -benzyl-4-phenyl-cyclopentyl)-acetic acid;
1 R-cis)-(l -Ammomethyl-2-methyl-cyclopentyl)-acetic acid; 1 S-cis)-(l -Aminomethyl-2-methyl-cyclopentyl)-acetic acid; lR-trans)-(l -Aminomethyl-2-methyl-cyclopentyl)-acetic acid; 1 S-trans)-(l -Aminomethyl-2-methyl-cyclopentyl)-acetic acid; (R)-(l -Aminomethyl-2,2-dimethyl-cyclopentyl)-acetic acid; S)-(l -Aminomethyl-2,2-dimethyl-cyclopentyl)-acetic acid; l-Aminomethyl-2,2,5,5-tetramethyl-cyclopentyl)-acetic acid; 1 ,2β,5β)-(l -Aminomethyl-2,5-dimethyl-cyclopentyl)-acetic acid; 2R, 5R)-(l-Aminomethyl-2,5-dimethyl-cyclopentyl)-acetic acid; 2S, 5S)-(l-Aminomethyl-2,5-dimethyl-cyclopentyl)-acetic acid; 1 ,2α,5α)-(l -Aminomethyl-2,5-dimethyl-cyclopentyι)-acetic acid; 1 R-(l α,2α,3 α)] -( 1 -Aminomethy 1-2,3 -dimethyl-cyclopentyl)-acetic acid; 1 R-(l α,2β,3 )] -( 1 -Aminomethyl-2,3 -dimethyl-cyclopentyl)-acetic acid; lR-(lα,2α,3β)]-(l-Aminomethyl-2,3-dimethyl-cyclopentyl)-acetic acid; lR-(lα,2β,3β)]-(l-Aminomethyl-2,3-dimethyl-cyclopentyl)-acetic acid; 1 S-( 1 α,2α,3 )] -( 1 -Aminomethyl-2,3 -dimethyl-cyclopentyl)-acetic acid; lS-(l ,2β,3 )]-(l-Aminomethyl-2,3-dimethyl-cyclopentyl)-acetic acid; lS-(l ,2α,3β)]-(l-Aminomethyl-2,3-dimethyl-cyclopentyl)-acetic acid; lS-(l ,2β,3β)]-(l-Aminomethyl-2,3-dimethyl-cyclopentyl)-acetic acid; 1 R-(l α,2oc,4oc)]-(l -Aminomethyl-2,4-dimethyl-cyclopentyl)-acetic acid; 1 S-(l α,2α,4 )]-(l -Aminomethyl-2,4-dimethyl-cyclopentyl)-acetic acid; 1R-(1 α,2α,4β)]-(l -Aminomethyl-2,4-dimethyl-cyclopentyl)-acetic acid;
[lS-(lα,2 ,4β)]-(l-Aminomethyl-2,4-dimethyl-cyclopentyl)-acetic acid; [ 1 R-( 1 α,2β,4 )] -(1 -Aminomethyl-2,4-dimethyl-cyclopentyl)-acetic acid; [1 S-(l α,2β,4α)]-(l -Aπιinomethyl-2,4-dimethyl-cyclopentyl)-acetic acid; [lR-(lα,2β,4β)]-(l-Aminomethyl-2,4-dimethyl-cyclopeιiιyl)-acetic acid; and
[1 S-(l α,2β,4β)]-(l -Aminomethyl-2,4-dimethyl-cyclopentyl)-acetic acid. Especially useful as an agent for insomnia and related disorders is (3S, 4S)-(l-Aminomethyl-3,4-dimethyl-cyclopentyl)-acetic acid.
Also, especially useful as an agent for insomnia and related disorders is (3S, 5R)-3-Aminomethyl-5-methyl-octanoic acid.
The term "lower alkyl" is a straight or branched group of from 1 to 4 carbons.
The term "alkyl" is a straight or branched group of from 1 to 6 carbon atoms including but not limited to methyl, ethyl, propyl, n-propyl, isopropyl, butyl, 2-butyl, tert-butyl, pentyl, except as where otherwise stated.
The benzyl and phenyl groups may be unsubstituted or substituted by from 1 to 3 substituents selected from hydroxy, carboxy, carboalkoxy, halogen, CF3, nitro, alkyl, and alkoxy. Preferred are halogens.
Since amino acids are amphoteric, pharmacologically compatible salts when R is hydrogen can be salts of appropriate inorganic or organic acids, for example, hydrochloric, sulphuric, phosphoric, acetic, oxalic, lactic, citric, malic, salicylic, malonic, maleic, succinic, methanesulfonic acid, and ascorbic. Starting from corresponding hydroxides or carbonates, salts with alkali metals or alkaline earth metals, for example, sodium, potassium, magnesium, or calcium are formed. Salts with quaternary ammonium ions can also be prepared with, for example, the tetramethyl-ammonium ion. The carboxyl group of the amino acids can be esterified by known means.
Certain of the compounds of the present invention can exist in unsolvated forms as well as solvated forms, including hydrated forms. In general, the solvated forms, including hydrated forms, are equivalent to unsolvated forms and are intended to be encompassed within the scope of the present invention.
Certain of the compounds of the present invention possess one or more chiral centers and each center may exist in the R(D) or S(L) configuration. The present invention includes all enantiomeric and epimeric forms as well as the appropriate mixtures thereof.
METHODS AND MATERIALS
Methods
Male Sprague-Dawley rats weighing 250 to 360 g were used for the experiment. The rats were kept on a 12: 12-hr light/dark cycle (lights on at 0900) at 23 ± 1°C ambient temperature. They had free access water and food during the experiment. Stainless steel jewelry screws for EEG recording were placed over the frontal and parietal cortices. An EMG electrode was implanted in the dorsal neck muscles.
Recording and analyses. After the recovery period (at least 1 week), rats were moved to sleep recording chambers. The rats were allowed relatively unrestricted movement inside the recording cages. A flexible tether connected the electrodes led to an electronic swivel. The leads from the swivel were routed to Grass Model No. 7D polygraphs in an adjacent room for recording EEG and EMG activity. The vigilance states of wakefulness, nonrapid-eye-movement sleep (NREMS), and rapid-eye-movement sleep (REMS) were determined offline in 10 second epochs. The amount of time spent in each vigilance state was calculated every hour and totaled for the 12-hour period postinjection. Drug or vehicle were administered PO just prior to the onset of the light phase of the rat's light dark cycle. Each rat received a vehicle and one drug dose.
Results (3S, 4S)-l-Aminomethyl-3,4-dimethyl-cyclopentyl)-acetic acid
(Compound 1), 3, 10, and 30 mg/kg PO and (3S, 5R)-3-Aminomethyl-5-methyl- octanoic acid (Compound 2), 1, 3, and 20 mg/kg PO significantly increased NREMS in rats during the 12-hour period following injection (Table 1 and
Table 2, respectively). This increase in NREMS sleep in rats is the typical profile demonstrated by agents that are used as sleep-inducing agents in humans (Meltzer L.T. and Serpa K.A., Assessment of hypnotic effects in the rat: Influence of the sleep-awake cycle, Drug Development Research 1988;14:151-159; Depoortere H. et al., Hypnotics: Clinical value of pharmaco-EEG methods, Neuropsychobiology 1986; 16 : 157- 162).
TABLE 1. Compound 1 Increases NREMS Sleep in Rats (N = 8/Treatment)
Total Minutes (Mean ± SEM) NREMS for
12-Hour Postinjection
Compound 1 (mg/kg PO) Vehicle Drug
3 370 + 11 401 ± 8*
10 383 + 8 409 + 12*
30 371 + 14 424 ± 6*
P <0.05 vs Vehicle (paired t-test)
TABLE 2. Compound 2 Increases NREMS Sleep in Rats (N = 8/Treatment)
Total Minutes (Mean + SEM) NREMS for 12-Hour Postinjection
Compound 2 (mg/kg PO) Vehicle Drug
1 409 + 8 432 + 8*
3 406 + 9 451 + 9* 20 412 + 6 481 + 6*
P <0.05 vs Vehicle (paired t-test)
The compounds of the present invention can be prepared and administered in a wide variety of oral and parenteral dosage forms. Thus, the compounds of the present invention can be administered by injection, that is, intravenously, intramuscularly, intracutaneously, subcutaneously, intraduodenally, or intraperitoneally. Also, the compounds of the present invention can be administered by inhalation, for example, intranasally. Additionally, the compounds of the present invention can be administered transdermally. It will be
obvious to those skilled in the art that the following dosage forms may comprise as the active component, either a compound of formula 1 or 1 A or a corresponding pharmaceutically acceptable salt of a compound of formula 1 or 1A.
For preparing pharmaceutical compositions from the compounds of the present invention, pharmaceutically acceptable carriers can be either solid or liquid. Solid form preparations include powders, tablets, pills, capsules, cachets, suppositories, and dispersible granules. A solid carrier can be one or more substances which may also act as diluents, flavoring agents, binders, preservatives, tablet disintegrating agents, or an encapsulating material. In powders, the carrier is a finely divided solid which is in a mixture with the finely divided active component.
In tablets, the active component is mixed with the carrier having the necessary binding properties in suitable proportions and compacted in the shape and size desired. The powders and tablets preferably contain from five or ten to about seventy percent of the active compound. Suitable carriers are magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, a low melting wax, cocoa butter, and the like. The term "preparation" is intended to include the formulation of the active compound with encapsulating material as a carrier providing a capsule in which the active component, with or without other carriers, is surrounded by a carrier, which is thus in association with it. Similarly, cachets and lozenges are included. Tablets, powders, capsules, pills, cachets, and lozenges can be used as solid dosage forms suitable for oral administration. For preparing suppositories, a low melting wax, such as a mixture of fatty acid glycerides or cocoa butter, is first melted, and the active component is dispersed homogeneously therein, as by stirring. The molten homogenous mixture is then poured into convenient sized molds, allowed to cool, and thereby to solidify. Liquid form preparations include solutions, suspensions, and emulsions, for example, water or water propylene glycol solutions. For parenteral injection
liquid preparations can be formulated in solution in aqueous polyethylene glycol solution.
Aqueous solutions suitable for oral use can be prepared by dissolving the active component in water and adding suitable colorants, flavors, stabilizing and thickening agents as desired.
Aqueous suspensions suitable for oral use can be made by dispersing the finely divided active component in water with viscous material, such as natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, and other well-known suspending agents. Also included are solid form preparations which are intended to be converted, shortly before use, to liquid form preparations for oral administration. Such liquid forms include solutions, suspensions, and emulsions. These preparations may contain, in addition to the active component, colorants, flavors, stabilizers, buffers, artificial and natural sweeteners, dispersants, thickeners, solubilizing agents, and the like.
The pharmaceutical preparation is preferably in unit dosage form. In such form the preparation is subdivided into unit doses containing appropriate quantities of the active component. The unit dosage form can be a packaged preparation, the package containing discrete quantities of preparation, such as packeted tablets, capsules, and powders in vials or ampoules. Also, the unit dosage form can be a capsule, tablet, cachet, or lozenge itself, or it can be the appropriate number of any of these in packaged form.
The quantity of active component in a unit dose preparation may be varied or adjusted from 0.1 mg to 1 g according to the particular application and the potency of the active component. In medical use the drug may be administered three times daily as, for example, capsules of 100 or 300 mg. The composition can, if desired, also contain other compatible therapeutic agents.
In therapeutic use, the compounds utilized in the pharmaceutical method of this invention are administered at the initial dosage of about 0.01 mg to about 100 mg/kg daily. A daily dose range of about 0.01 mg to about 100 mg/kg is preferred. The dosages, however, may be varied depending upon the requirements of the patient, the severity of the condition being treated, and the compound being
employed. Determination of the proper dosage for a particular situation is within the skill of the art. Generally, treatment is initiated with smaller dosages which are less than the optimum dose of the compound. Thereafter, the dosage is increased by small increments until the optimum effect under the circumstances is reached. For convenience, the total daily dosage may be divided and administered in portions during the day, if desired.
Claims (1)
- A method of treating sleep disorders in a mammal in need of said treatment comprising administering a therapeutically effective amount of a compound of formula1 1A or a pharmaceutically acceptable salt thereof wherein: R is hydrogen or a lower alkyl;Ri to R1^ are each independently selected from hydrogen, straight or branched alkyl of from 1 to 6 carbons, phenyl, benzyl, fluorine, chlorine, bromine, hydroxy, hydroxymethyl, amino, aminomethyl, trifluoromethyl, -CO2H, -CO2R15, -CH2CO2H, -CH CO2Rl5,-OR1 ^ wherein Rl5 is a straight or branched alkyl of from 1 to6 carbons, phenyl, or benzyl, and R1 to R^ are not simultaneously hydrogen.A method according to Claim 1 wherein R1 to R1^ are selected from hydrogen, methyl, ethyl, propyl, isopropyl, butyl straight or branched, phenyl, or benzyl.A method according to Claim 1 wherein R1 to R1^ are selected from hydrogen, methyl, ethyl, or benzyl.A method according to Claim 1 wherein the compound administered is selected from: (+)-(trans)-( 1 -Aminomethyl-3 ,4-dimethyl-cyclopentyl)-acetic acid hydrochloride;(l-Aminomethyl-cyclobutyl)-acetic acid hydrochloride; (cis/trans)-(3R)-(l -Aminomethyl-3-methyl-cyclopentyl)-acetic acid hydrochloride;(cis/trans)-( 1 -Aminomethyl-3 -benzyl-cyclobutyl)-acetic acid hydrochloride;(+)-(l -Aminomethyl-3 ,3-dimethyl-cyclopentyl)-acetic acid hydrochloride; and (cis)-(3R)-(l-Aminomethyl-3-methyl-cyclopentyl)-acetic acid hydrochloride.5. A method according to Claim 1 wherein the compound administered is selected from:(lα,3 ,4 )-(l-Aminomethyl-3,4-dimethyl-cyclopentyl)-acetic acid; (loc,3α,4α)-(l-Aminomethyl-3,4-diethyl-cyclopentyl)-acetic acid;( 1 α,3 α,4α)-( 1 -Aminomethyl-3 ,4-diisopropyl-cyclopentyl)-acetic acid;[1 S-(l α,3α,4α)]-(l -Aminomethyl-3-ethyl-4-methyl-cyclopentyl)- acetic acid; [1R-(1 ,3α,4α)]-(l -Aminomethyl-3-ethyl-4-methyl-cyclopentyl)- acetic acid;[1 S-(l ,3 ,4 )]-(l -Aminomethyl-3-isopropyl-4-methyl- cyclopentyl)-acetic acid;[ 1 R-( 1 ,3 α,4 )] -(1 -Aminomethyl-3 -isopropyl-4-methyl- cyclopentyl)-acetic acid;[1 S-(l ,3 ,4α)]-(l -Aminomethyl-3-ethyl-4-isopropyl- cyclopentyl)-acetic acid;[lR-(l ,3 ,4α)]-(l-Aminomethyl-3-ethyl-4-isopropyl- cyclopentyl)-acetic acid; [1 S-(l α,3α,4α)]-(l -Aminomethyl-3-tert-butyl-4-methyl- cyclopentyl)-acetic acid;[lR-(lα,3α,4α)]-(l-Aminomethyl-3-tert-butyl-4-methyl- cyclopentyl)-acetic acid; [lS-(l ,3α,4α)]-(l-Aminomethyl-3-tert-butyl-4-ethyl- cyclopentyl)-acetic acid;[lR-(lα,3α,4α)]-(l-Aminomethyl-3-tert-butyl-4-ethyl- cyclopentyl)-acetic acid;[lS-(l ,3 ,4 )]-(l-Aminomethyl-3-tert-butyl-4-isopropyl- cyclopentyl)-acetic acid;[ 1 R-(l ,3 α,4 )] -(1 -Aminomethyl-3 -tert-butyl-4-isopropyl- cyclopentyl)-acetic acid;(1 α,3 ,4α)-(l -Aminomethyl-3 ,4-di-tert-butyl-cyclopentyl)-acetic acid; [lS-(l ,3 ,4 )]-(l-Aminomethyl-3-methyl-4-phenyl-cycloρentyl)- acetic acid;[ 1 R-( 1 α,3 α,4 )] -(1 -Aminomethyl-3 -methyl-4-phenyl-cyclopentyl)- acetic acid;[1 S-(l ,3 ,4 )]-(l-Aminomethyl-3-benzyl-4-methyl-cyclopentyl)- acetic acid;[ 1 R-( 1 α,3 α,4 )] -(1 -Aminomethyl-3 -benzyl-4-methyl-cyclopentyl)- acetic acid;(1 S-cis)-(l -Aminomethyl-3 -methyl-cyclopentyl)-acetic acid; (1 S-cis)-(l -Aminomethyl-3 -ethyl-cyclopentyl)-acetic acid; (lS-cis)-(l-Aminomethyl-3-isopropyl-cyclopentyl)-acetic acid;(1 S-cis)-(l -Aminomethyl-3 -tert-butyl-cyclopentyl)-acetic acid; (1 S-cis)-(l-Aminomethyl-3-phenyl-cyclopentyl)-acetic acid; (1 S-cis)-(l -Aminomethyl-3-benzyl-cyclopentyl)-acetic acid; (1 R-cis)-(l -Aminomethyl-3 -methyl-cyclopentyl)-acetic acid; (lR-cis)-(l-Aminomethyl-3-ethyl-cyclopentyl)-acetic acid;(lR-cis)-(l-Aminomethyl-3-isopropyl-cyclopentyl)-a.cetic acid; ( 1 R-cis)-( 1 -Aminomethyl-3 -tert-butyl-cyclopentyl)-acetic acid;( 1 R-cis)-( 1 -Aminomethyl-3 -phenyl-cyclopentyl)-acetic acid;( 1 R-cis)-( 1 -Aminomethyl-3 -benzyl-cyclopentyl)-acetic acid;(S)-(l -Aminomethyl-3, 3 -dimethyl-cyclopentyl)-acetic acid; (S)-(l -Aminomethyl-3 ,3 -diethyl-cyclopentyl)-acetic acid;(1 -Aminomethyl-3, 3, 4,4-tetramethyl-cyclopentyl)-acetic acid;( 1 -Aminomethyl-3 ,3 ,4,4-tetraethyl-cyclopentyl)-acetic acid;(1 α,3 β,4β)-(l -Aminomethyl-3 ,4-dimethyl-cyclopentyl)-acetic acid;(1 ,3 β,4β)-(l -Aminomethyl-3 ,4-diethyl-cyclopentyl)-acetic acid; ( 1 α,3 β,4β)-(l -Aminomethyl-3 ,4-diisopropyl-cyclopentyl)-acetic acid;[lR-(lα,3β,4β)]-(l-Aminomethyl-3-ethyl-4-methyl-cyclopentyl)- acetic acid;[lS-(lα,3β,4β)]-(l-Aminomeιfryl-3-etlιyl-4-methyl-cyclopentyl)- acetic acid;[lR-(lα,3β,4β)]-(l-Aminomethyl-3-isopropyl-4-methyl- cyclopentyl)-acetic acid;[lS-(lα,3β,4β)]-(l-Aminomethyl-3-isopropyl-4-methyl- cyclopentyl)-acetic acid; [lR-(lα,3β,4β)]-(l-Aminomethyl-3-ethyl-4-isoproρyl- cyclopentyl)-acetic acid;[lS-(loc,3β,4β)]-(l -Aminomethyl-3 -ethyl-4-isopropyl-cyclopentyl)- acetic acid;[lR-(lα,3β,4β)]-(l-Aminomethyl-3-tert-butyl-4-methyl- cyclopentyl)-acetic acid;[ 1 S-( 1 α,3 β,4β)]-(l -Aminomethyl-3-tert-butyl-4-methyl- cyclopentyl)-acetic acid;[ 1 R-(l ,3 β,4β)]-(l -Aminomethyl-3-tert-butyl-4-ethyl- cyclopentyl)-acetic acid; [lS-(lα,3β,4β)]-(l-Aminomethyl-3-tert-butyl-4-ethyl-cyclopentyl)- acetic acid;[lR-(lα,3β,4β)]-(l-Aminomethyl-3-tert-butyl-4-isopropyl- cyclopentyl)-acetic acid; [lS-(lα,3β,4β)]-(l-Aminomethyl-3-tert-butyl-4-isopropyl- cyclopentyl)-acetic acid;(lα,3β,4β)-(l-Aminomethyl-3,4-di-tert-butyl-cyclopentyl)-acetic acid;[lR-(l ,3β,4β)]-(l-Aminomethyl-3-methyl-4-phenyl-cyclopentyl)- acetic acid;[lS-(lα,3β,4β)]-(l-Aminomethyl-3-methyl-4-phenyl-cyclopentyl)- acetic acid;[ 1 R-(l α,3 β,4β)] -( 1 -Aminomethyl-3 -benzyl-4-methyl-cyclopentyl)- acetic acid; [1 S-(l α,3 β,4β)]-(l -Aminomethyl-3-benzyl-4-methyl-cyclopentyl)- acetic acid;( 1 R-trans)-( 1 -Aminomethyl-3 -methyl-cyclopentyI)-acetic acid; (lR-trans)-(l -Aminomethyl-3 -ethyl-cyclopentyl)-acetic acid; (lR-trans)-(l -Aminomethyl-3 -isopropyl-cyclopentyl)-acetic acid; (lR-trans)-(l-Aminomethyl-3-tert-butyl-cyclopentyl)-acetic acid;(1 R-trans)-(l -Aminomethyl-3-phenyl-cyclopentyl)-acetic acid; (lR-frans)-(l-Aminomethyl-3-benzyl-cyclopentyl)-acetic acid; (1 S-trans)-(l -Aminomethyl-3-methyl-cyclopentyl)-acetic acid; (1 S-trans)-(l -Aminomethyl-3-ethyl-cyclopentyl)-acetic acid; (1 S-trans)-( 1 -Aminomethyl-3 -isopropyl-cyclopentyl)-acetic acid;(1 S-trans)-(l-Aminomethyl-3-tert-butyl-cyclopentyl)-acetic acid; ( 1 S-trans)-( 1 -Aminomethyl-3 -phenyl-cyclopentyl)-acetic acid; (lS-trans)-(l-Aminomethyl-3-benzyl-cyclopentyl)-acetic acid; (R)-( 1 -Aminomethyl-3 ,3 -dimethyl-cyclopentyl)-acetic acid; (R)-(l-Aminomethyl-3,3-diethyl-cyclopentyl)-acetic acid; cis-(l -Aminomethyl-3 -methyl-cyclobutyl)-acetic acid; cis-(l-Aminomethyl-3-ethyl-cyclobutyl)-acetic acid; cis-(l-An inomethyl-3-isopropyl-cyclobutyl)-acetic acid; cis-(l-Aminomethyl-3-tert-butyl-cyclobutyl)-acetic acid; cis-(l -Aminomethyl-3-phenyl-cyclobutyl)-acetic acid; cis-(l-Aminomethyl-3-benzyl-cyclobutyl)-acetic acid; trans-(l -Aminomethyl-3-methyl-cyclobutyl)-acetic acid; trans-(l -Aminomethyl-3-ethyl-cyclobutyl)-acetic acid; trans-(l -Aminomethyl-3-isopropyl-cyclobutyl)-acetic acid; trans-(l -Aminomethyl-3-tert-butyl-cyclobutyl)-acetic acid; trans-(l-Aminomethyl-3-phenyl-cyclobutyl)-acetic acid; trans-(l -Aminomethyl-3-benzyl-cyclobutyl)-acetic acid; cis-(l -Aminomethyl-3-ethyl-3-methyl-cyclobutyl)-acetic acid; cis-(l -Aminomethyl-3-isopropyl-3-methyl-cyclobutyl)-acetic acid; cis-(l -Aminomethyl-3 -tert-butyl-3 -methyl-cyclobutyl)-acetic acid; cis-(l-Aminomethyl-3-methyl-3-phenyl-cyclobutyl)-acetic acid; cis-(l-Aminomethyl-3-benzyl-3-methyl-cyclobutyl)-acetic acid; trans-(l -Aminomethyl-3-ethyl-3-methyl-cyclobutyl)-acetic acid; trans-(l-Aminomethyl-3-isopropyl-3-methyl-cyclobutyl)-acetic acid; trans-(l -Aminomethyl-3 -tert-butyl-3 -methyl-cyclobutyl)-acetic acid; trans-(l -Aminomethyl-3 -methyl-3-phenyl-cyclobutyl)-acetic acid; trans-(l -Aminomethyl-3 -benzyl-3 -methyl-cyclobutyl)-acetic acid; cis-(l -Aminomethyl-3-ethyl-3-isopropyl-cyclobutyl)-acetic acid; cis-(l-Aminomethyl-3-tert-butyl-3-ethyl-cyclobutyl)-acetic acid; cis-(l -Aminomethyl-3-ethyl-3-phenyl-cyclobutyl)-acetic acid; cis-(l-Aminomethyl-3-benzyl-3-ethyl-cyclobutyl)-acetic acid; trans-(l -Aminomethyl-3 -ethyl-3 -isopropyl-cyclobutyl)-acetic acid; trans-(l -Aminomethyl-3 -tert-butyl-3 -ethyl-cyclobutyl)-acetic acid; trans-( 1 -Aminomethyl-3 -ethyl-3 -phenyl-cyclobutyl)-acetic acid; trans-(l -Aminomethyl-3 -benzyl-3 -ethyl-cyclobutyl)-acetic acid; cis-(l-Aminomethyl-3-tert-butyl-3-isopropyl-cyclobutyl)-acetic acid; cis-(l -Aminomethyl-3 -isopropyl-3 -phenyl-cyclobutyl)-acetic acid; trans-( 1 -Aminomethyl-3 -benzyl-3 -isopropyl-cyclobutyl)-acetic acid; cis-( 1 -Aminomethyl-3 -tert-butyl-3 -phenyl-cyclobutyl)-acetic acid; trans-( 1 -Aminomethyl-3 -benzyl-3 -tert-butyl-cyclobutyl)-acetic acid; trans-( 1 -Aminomethyl-3 -tert-butyl-3 -isopropyl-cyclobutyl)-acetic acid; trans-(l-Aminomethyl-3-isopropyl-3-phenyl-cyclobutyl)-acetic acid; cis-(l-Aminomethyl-3-benzyl-3-isopropyl-cyclobutyl)-acetic acid; trans-(l-Aminomethyl-3-tert-butyl-3-phenyl-cyclobutyl)-acetic acid; cis-( 1 -Aminomethyl-3 -benzyl-3 -tert-butyl-cyclobutyl)-acetic acid;( 1 -Aminomethyl-3 ,3 -dimethyl-cyclobutyl)-acetic acid;( 1 -Aminomethyl-3 ,3 -diethyl-cyclobutyl)-acetic acid;( 1 -Aminomethyl-3 ,3 -diisopropyl-cyclobutyl)-acetic acid; (1 -Aminomethyl-3 ,3 -di-tert-butyl-cyclobutyl)-acetic acid;( 1 -Aminomethyl-3 ,3 -diphenyl-cyclobutyl)-acetic acid;(l-Aminomethyl-3,3-dibenzyl-cyclobutyl)-acetic acid;( 1 - Aminomethyl-2,2,4,4-tetramethyl-cyclobutyl)-acetic acid;(1 -Aminomethyl-2,2,3,3,4,4-hexamethyl-cyclobutyl)-acetic acid; (R)-( 1 -Aminomethyl-2,2-dimethyl-cyclobutyl)-acetic acid;(S)-(l -Aminomethyl-2,2-dimethyl-cyclobutyl)-acetic acid;(lR-cis)-(l-Aminomethyl-2-methyl-cyclobutyl)-acetic acid;[ 1 R-(l α,2α,3 )] -( 1 -Aminomethyl-2,3 -dimethyl-cyclobutyl)-acetic acid; (1 α,2α,4α)-(l -Aminomethyl-2,4-dimethyl-cyclobutyl)-acetic acid; [1R-(1 α,2α,3 β)]-(l -Aminomethyl-2,3-dimethyl-cyclobutyl)-acetic acid;(lα,2 ,4β)-(l-Aminomethyl-2,4-dimethyl-cyclobutyl)-acetic acid; (1 S-trans)-(l-Aminomethyl-2-methyl-cyclobutyl)-acetic acid; [lS-(lα,2β,3β)]-(l-Aminomethyl-2,3-dimethyl-cyclobutyl)-acetic acid;(lα,2β,4β)- (l-Aminomethyl-2,4-dimethyl-cyclobutyl)-acetic acid; [lS-(lα,2β,3α)]-(l-Aminomethyl-2,3-dimethyl-cyclobutyl)-acetic acid; (lα,2β,4α)-(l-Aminomethyl-2,4-dimethyl-cyclobutyl)-acetic acid;( 1 R-trans)-( 1 - Aminomethyl-2-methyl-cyclobutyl)-acetic acid; [lR-(lα,2β,3β)]-(l-Aminomethyl-2,3-dimethyl-cyclobutyl)-acetic acid;[1R-(1 ,2β,4β)]-(l -Aminomethyl-2-ethyl-4-methyl-cyclobutyl)- acetic acid;[ 1 R-( 1 α,2β,3 α)] -(1 -Aminomethyl-2,3 -dimethyl-cyclobutyl)-acetic acid;(1 α,2β,4α)-(l -Aminomethyl-2,4-dimethyl-cyclobutyl)-acetic acid; (1 S-cis)-(l -Aminomethyl-2-methyl-cyclobutyl)-acetic acid; [ 1 S -( 1 α,2α,3 α)] -( 1 -Aminomethyl-2,3 -dimethyl-cyclobutyl)-acetic acid;[ 1 S-( 1 α,2α,3 α)] -( 1 -Aminomethyl-2,4-dimethyl-cyclobutyl)-acetic acid;[ 1 S-( 1 α,2β,3 α)] -( 1 -Aminomethyl-2,3 -dimethyl-cyclobutyl)-acetic acid;(1 α,2α,4β)-(l-Aminomethyl-2,4-dimethyl-cyclobutyl)-acetic acid; (3R, 4R)-(1 -Aminomethyl-3 ,4-dimethyl-cyclopentyl)-acetic acid; (3S, 4S)-(1 -Aminomethyl-3 ,4-diethyl-cyclopentyl)-acetic acid; (3R, 4R)-(1 -Aminomethyl-3 ,4-diethyl-cyclopentyl)-acetic acid; (3S, 4S)-(1 -Aminomethyl-3 ,4-diisopropyl-cyclopentyl)-acetic acid; (3R, 4R)-(1 -Aminomethyl-3 ,4-diisopropyl-cyclopentyl)-acetic acid; (3S, 4S)-(1 -Aminomethyl-3 ,4-di-tert-butyl-cyclopentyl)-acetic acid; (3R, 4R)-(1 -Aminomethyl-3 ,4-di-tert-butyl-cyclopentyl)-acetic acid; (3S, 4S)-(l-Aminomethyl-3,4-diphenyl-cyclopentyl)-acetic acid;(3R, 4R)-(1 -Aminomethyl-3 ,4-diphenyl-cyclopentyι)-acetic acid; (3S, 4S)-(l-Aminomethyl-3,4-dibenzyl-cyclopentyl)-acetic acid; (3R, 4R)-(1 - Aminomethyl-3, 4-dibenzyl-cyclopentyl)-acetic acid; [1 S-(l ,3α,4β)]-(l -Aminomethyl-3-methyl-4-ethyl-cyclopentyl)- acetic acid;[1R-(1 α,3 β,4α)]-(l -Aminomethyl-3-methyl-4-ethyl-cyclopentyl)- acetic acid;[lR-(lα,3α,4β)]-(l-Aminomethyl-3-methyl-4-ethyl-cyclopentyl)- acetic acid; [1 S-(l α,3β,4α)]-(l -Aminomethyl-3-methyl-4-ethyl-cyclopentyl)- acetic acid;[1 S-(l α,3α,4β)]-(l -Aminomethyl-3-methyl-4-isopropyl- cyclopentyl)-acetic acid;[lR-(lα,3β,4α)]-(l-Aminomethyl-3-methyl-4-isopropyl- cyclopentyl)-acetic acid;[lR-(l ,3α,4β)]-(l-Aminomethyl-3-methyl-4-isopropyl- cyclopentyl)-acetic acid;[lS-(l ,3β,4α)]-(l-Aminomethyl-3-methyl-4-isopropyl- cyclopentyl)-acetic acid; [lS-(l ,3α,4β)]-(l-Aminomethyl-3-methyl-4-tert-butyl- cyclopentyl)-acetic acid;[lR-(lα,3β,4 )]-(l-Aminomethyl-3-methyl-4-tert-butyl- cyclopentyl)-acetic acid;[lR-(l ,3α,4β)]-(l-Aminomethyl-3-methyl-4-tert-butyl- cyclopentyl)-acetic acid; [lS-(l ,3β,4β)]-(l-Aminomethyl-3-methyl-4-tert-butyl- cyclopentyl)-acetic acid;[lS-(l ,3α,4β)]-(l-Aminomethyl-3-methyl-4-phenyl-cyclopentyl)- acetic acid; [lR-(lα,3β,4α)]-(l-Aminomethyl-3-methyl-4-phenyl-cyclopentyl)- acetic acid;[lR-(l ,3 ,4β)]-(l-Aminomethyl-3-methyl-4-phenyl-cyclopentyl)- acetic acid;[lS-(l ,3β,4 )]-(l-Aminomethyl-3-methyl-4-phenyl-cyclopentyl)- acetic acid;[1 S-(l ,3α,4β)]-(l -Aminomethyl-3-benzyl-4-methyl-cyclopentyl)- acetic acid;[lR-(lα,3β,4 )]-(l-Aminomethyl-3-benzyl-4-methyl-cyclopentyl)- acetic acid; [lR-(l ,3α,4β)]-(l-Aminomethyl-3-benzyl-4-methyl-cyclopentyl)- acetic acid;[lS-(lα,3β,4α)]-(l-Aminomethyl-3-benzyl-4-methyl-cyclopentyl)- acetic acid;[lS-(lα,3 ,4β)]-(l-Aminomethyl-3-ethyl-4-isopropyl- cyclopentyl)-acetic acid;[lR-(lα,3β,4α)]-(l-Aminomethyl-3-ethyl-4-isopropyl- cyclopentyl)-acetic acid;[lR-(l ,3 ,4β)]-(l-Aminomethyl-3-ethyl-4-isopropyl- cyclopentyl)-acetic acid; [lS-(l ,3β,4α)]-(l-Aminomethyl-3-ethyl-4-isopropyl- cyclopentyl)-acetic acid;[lS-(l ,3 ,4β)]-(l-Aminomethyl-3-tert-butyl-4-ethyl- cyclopentyl)-acetic acid;[lR-(l ,3β,4α)]-(l-Aminomethyl-3-tert-butyl-4-ethyl- cyclopentyl)-acetic acid; [lR-(lα,3α,4β)]-(l-Aminomethyl-3-tert-butyl-4-ethyl- cyclopentyl)-acetic acid;[lS-(lα,3β,4α)]-(l-Aminomethyl-3-tert-butyl-4-ethyl- cyclopentyl)-acetic acid; [1 S-(l α,3α,4β)]-(l -Aminomethyl-3-ethyl-4-phenyl-cyclopentyl)- acetic acid;[lR-(lα,3β,4α)]-(l-Aminomethyl-3-ethyl-4-phenyl-cyclopentyl)- acetic acid;[lR-(lα,3α,4β)]-(l-Aminomethyl-3-ethyl-4-phenyl-cyclopentyl)- acetic acid;[lS-(lα,3β,4α)]-(l-Aminomethyl-3-ethyl-4-phenyl-cyclopentyl)- acetic acid;[lS-(lα,3α,4β)]-(l-Aminomethyl-3-benzyl-4-ethyl-cyclopentyl)- acetic acid; [1 R-(l α,3β,4α)]-(l -Aminomethyl-3-benzyl-4-ethyl-cyclopentyl)- acetic acid;[lR-(lα,3α,4β)]-(l-Aminomethyl-3-benzyl-4-ethyl-cyclopentyl)- acetic acid;[lS-(lα,3β,4 )]-(l-Aminomethyl-3-benzyl-4-ethyl-cyclopentyl)- acetic acid;[lS-(lα,3 ,4β)]-(l-Aminomethyl-3-tert-butyl-4-isopropyl- cyclopentyl)-acetic acid;[lR-(lα,3β,4 )]-(l-Aminomethyl-3-tert-butyl-4-isopropyl- cyclopentyl)-acetic acid; [lR-(l ,3 ,4β)]-(l-Aminomethyl-3-tert-butyl-4-isopropyl- cyclopentyl)-acetic acid;[lS-(lα,3β,4α)]-(l-Aminomethyl-3-tert-butyl-4-isopropyl- cyclopentyl)-acetic acid;[1 S-(l α,3 ,4β)]-(l -Aminomethyl-3-isopropyl-4-phenyl- cyclopentyl)-acetic acid; [lR-(lα,3β,4 )]-(l-Aminomethyl-3-isopropyl-4-phenyl- cyclopentyl)-acetic acid;[lR-(lα,3 ,4β)]-(l-Aminomethyl-3-isopropyl-4-phenyl- cyclopentyl)-acetic acid; [lS-(lα,3β,4α)]-(l-Aminomethyl-3-isopropyl-4-phenyl- cyclopentyl)-acetic acid;[1 S-(l α,3α,4β)]-(l -Aminomethyl-3-benzyl-4-isopropyl- cyclopentyl)-acetic acid;[lR-(lα,3β,4 )]-(l-Aminomethyl-3-benzyl-4-isopropyl- cyclopentyl)-acetic acid;[lR-(lα,3 ,4β)]-(l-Aminomethyl-3-benzyl-4-isopropyl- cyclopentyl)-acetic acid;[1 S-(l α,3 β,4α)]-(l -Aminomethyl-3 -benzyl-4-isopropyl- cyclopentyl)-acetic acid; [1 S-(l α,3α,4β)]-(l-Aminomethyl-3-tert-butyl-4-phenyl- cyclopentyl)-acetic acid;[lR-(l ,3β,4α)]-(l-Aminomethyl-3-tert-butyl-4-phenyl- cyclopentyl)-acetic acid;[lR-(lα,3α,4β)]-(l-Aminomethyl-3-tert-butyl-4-ρhenyl- cyclopentyl)-acetic acid;[lS-(lα,3β,4α)]-(l-Aminomethyl-3-tert-butyl-4-phenyl- cyclopentyl)-acetic acid;[ 1 R-(l α,3 α,4β)]-(l -Aminomethyl-3-benzyl-4-tert-butyl- cyclopentyl)-acetic acid; [ 1 S-(l α,3β,4α)]-(l -Aminomethyl-3-benzyl-4-tert-butyl- cyclopentyl)-acetic acid;[lS-(l ,3α,4β)]-(l-Aminomethyl-3-benzyl-4-tert-butyl- cyclopentyl)-acetic acid;[lR-(l ,3β,4α)]-(l-Aminomethyl-3-benzyl-4-tert-butyl- cyclopentyl)-acetic acid; [lS-(lα,3α,4β)]-(l-Aminomethyl-3-benzyl-4-phenyl-cyclopentyl)- acetic acid;[ 1 R-( 1 α,3 β,4α)] -( 1 -Aminomethyl-3 -benzyl-4-phenyl-cyclopentyl)- acetic acid; [ 1 R-(l α,3 ,4β)] -(1 -Aminomethyl-3 -benzyl-4-phenyl-cyclopentyl)- acetic acid;[lS-(lα,3β,4α)]-(l-Aminomethyl-3-benzyl-4-phenyl-cyclopentyl)- acetic acid;(lR-cis)-(l-Aminomethyl-2-methyl-cyclopentyl)-acetic acid; (lS-cis)-(l-Aminomethyl-2-methyl-cyclopentyl)-acetic acid;(1 R-trans)-(l -Aminomethyl-2-methyl-cyclopentyl)-acetic acid;(1 S-trans)-(l -Aminomethyl-2-methyl-cyclopentyI)-acetic acid;(R)-(l -Aminomethyl-2,2-dimethyl-cyclopentyl)-acetic acid;(S)-(l -Aminomethyl-2,2-dimethyl-cyclopentyl)-acetic acid; (l-Aminomethyl-2,2,5,5-tetramethyl-cyclopentyl)-acetic acid;(1 α,2β,5β)-(l -Aminomethyl-2,5-dimethyl-cyclopentyl)-acetic acid;(2R, 5R)-(l-Aminomethyl-2,5-dimethyl-cyclopentyl)-acetic acid;(2S, 5S)-(l-Aminomethyl-2,5-dimethyl-cyclopentyl)-acetic acid;(1 ,2 ,5 )-(l -Aminomethyl-2,5-dimethyl-cyclopentyl)-acetic acid; [1R-(1 α,2α,3α)]-(l -Aminomethyl-2,3-dimethyl-cyclopentyl)-acetic acid;[ 1 R-( 1 α,2β,3 α)] -( 1 -Aminomethyl-2,3 -dimethyl-cyclopentyl)-acetic acid;[ 1 R-(l ,2 ,3 β)] -( 1 -Aminomethyl-2,3 -dimethyl-cyclopentyl)-acetic acid;[ 1 R-( 1 cc,2β,3 β)] -( 1 -Aminomethyl-2,3 -dimethyl-cyclopentyl)-acetic acid;[lS-(lα,2α,3α)]-(l-Aminomethyl-2,3-dimethyl-cyclopentyl)-acetic acid; [1 S-(l ,2β,3α)]-(l-Aminomethyl-2,3-dimethyl-cyclopentyl)-acetic acid;[lS-(lα,2α,3β)]-(l-Aminomethyl-2,3-dimethyl-cyclopentyl)-acetic acid; [lS-(lα,2β,3β)]-(l-Aminomethyl-2,3-dimethyl-cyclopentyl)-acetic acid;[ 1 R-( 1 ,2 ,4α)] -(1 -Aminomethyl-2,4-dimethyl-cyclopentyl)-acetic acid;[1 S-(l α,2α,4α)]-(l-Aminomethyl-2,4-dimethyl-cyclopentyl)-acetic acid;[lR-(lα,2α,4β)]-(l-Aminomethyl-2,4-dimethyl-cyclopentyl)-acetic acid;[ 1 S-( 1 α,2α,4β)] -(1 -Aminomethyl-2,4-dimethyl-cyclopentyl)-acetic acid; [lR-(lα,2β,4α)]-(l-Aminomethyl-2,4-dimethyl-cyclopentyl)-acetic acid;[lS-(l ,2β,4α)]-(l-Aminomethyl-2,4-dimethyl-cyclopentyl)-acetic acid;[1 R-(l ,2β,4β)]-(l -Aminomethyl-2,4-dimethyl-cyclopentyl)-acetic acid; and[lS-(lα,2β,4β)]-(l-Aminomethyl-2,4-dimethyl-cyclopentyl)-acetic acid.6. A method according to Claim 1 wherein the compound administered is named (3S, 4S)-1 -Aminomethyl-3 ,4-dimethyl-cyclopentyl)-acetic acid.7. A method according to Claim 1 wherein the compound administered is named (3S, 5R)-3-Aminomethyl-5-methyl-octanoic acid.8. A method according to Claim 1 wherein the sleep disorder is insomnia.9. A method according to Claim 1 wherein the sleep disorder is insomnia, and the compound administered is named (3S, 4S)~(1 -Aminomethyl-3 ,4- dimethyl-cyclopentyl)-acetic acid.10. A method according to Claim 1 wherein the sleep disorder is insomnia, and the compound administered is named (3S, 5R)-3-Aminomethyl-5- methyl-octanoic acid.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21417100P | 2000-06-26 | 2000-06-26 | |
| US60/214,171 | 2000-06-26 | ||
| PCT/US2001/016343 WO2002000209A2 (en) | 2000-06-26 | 2001-05-18 | Gabapentin analogues for sleep disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2001264736A1 true AU2001264736A1 (en) | 2002-03-28 |
| AU2001264736B2 AU2001264736B2 (en) | 2006-04-27 |
Family
ID=22798045
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2001264736A Ceased AU2001264736B2 (en) | 2000-06-26 | 2001-05-18 | Gabapentin analogues for sleep disorders |
| AU6473601A Pending AU6473601A (en) | 2000-06-26 | 2001-05-18 | Gabapentin analogues for sleep disorders |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU6473601A Pending AU6473601A (en) | 2000-06-26 | 2001-05-18 | Gabapentin analogues for sleep disorders |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US7141606B2 (en) |
| EP (1) | EP1296671B1 (en) |
| JP (1) | JP3909842B2 (en) |
| KR (1) | KR100785182B1 (en) |
| CN (1) | CN1279900C (en) |
| AT (1) | ATE390133T1 (en) |
| AU (2) | AU2001264736B2 (en) |
| BR (1) | BR0111913A (en) |
| CA (1) | CA2414008C (en) |
| CZ (1) | CZ20024110A3 (en) |
| DE (1) | DE60133389T2 (en) |
| DK (1) | DK1296671T3 (en) |
| ES (1) | ES2300332T3 (en) |
| HK (1) | HK1056681A1 (en) |
| HU (1) | HUP0300833A3 (en) |
| IL (2) | IL152770A0 (en) |
| MX (1) | MXPA02010668A (en) |
| NZ (1) | NZ522480A (en) |
| PL (1) | PL359872A1 (en) |
| PT (1) | PT1296671E (en) |
| SK (1) | SK17922002A3 (en) |
| TW (1) | TWI298020B (en) |
| WO (1) | WO2002000209A2 (en) |
| ZA (1) | ZA200209418B (en) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GEP20053545B (en) | 2001-04-19 | 2005-06-10 | Warner Lambert Co | Fused Bicyclic or Tricyclic Amino Acids |
| US6818787B2 (en) | 2001-06-11 | 2004-11-16 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
| US7420002B2 (en) | 2001-06-11 | 2008-09-02 | Xenoport | Amino acid conjugates providing for sustained systemic concentrations of GABA analogues |
| US8048917B2 (en) | 2005-04-06 | 2011-11-01 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
| US7186855B2 (en) | 2001-06-11 | 2007-03-06 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
| CA2449673A1 (en) * | 2001-06-11 | 2002-12-19 | Xenoport, Inc. | Orally administered dosage forms of gaba analog prodrugs having reduced toxicity |
| AU2002316231A1 (en) | 2002-02-19 | 2003-09-29 | Xenoport, Inc. | Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof |
| AU2003222033A1 (en) | 2002-03-20 | 2003-10-08 | Xenoport | Cyclic 1-(acyloxy)-alkyl prodrugs of gaba analogs, compositions and uses thereof |
| US7183259B2 (en) | 2002-05-17 | 2007-02-27 | Xenoport | Amino acid conjugates providing for sustained systemic concentrations of GABA analogues |
| WO2004052360A1 (en) | 2002-12-11 | 2004-06-24 | Xenoport, Inc. | Prodrugs of fused gaba analogs, pharmaceutical compositions and uses thereof |
| BR0316751A (en) * | 2002-12-13 | 2005-10-25 | Warner Lambert Co | Gabapentin analogs for fibromyalgia and other related disorders |
| CA2451267A1 (en) * | 2002-12-13 | 2004-06-13 | Warner-Lambert Company Llc | Pharmaceutical uses for alpha2delta ligands |
| EP1622603A4 (en) * | 2003-03-25 | 2010-03-24 | Kiel Lab Inc | Phenolic acid salts of gabapentin in solid dosage forms and methods of use |
| JP2007505149A (en) | 2003-09-11 | 2007-03-08 | ゼノポート，インコーポレイティド | Treatment and / or prevention of urinary incontinence with prodrugs of GABA analogs |
| BRPI0414481A (en) | 2003-09-17 | 2006-11-14 | Xenoport Inc | methods of treating or preventing restless leg syndrome in a patient and improving sleep in a patient with restless leg syndrome, and, pharmaceutical composition |
| SG147437A1 (en) | 2003-10-14 | 2008-11-28 | Xenoport Inc | Crystalline form of gamma-aminobutyric acid analog |
| JP4613031B2 (en) * | 2004-05-06 | 2011-01-12 | エスエス製薬株式会社 | Hypnotic composition |
| JP2005325070A (en) * | 2004-05-14 | 2005-11-24 | Ss Pharmaceut Co Ltd | Sleep-improving agent |
| CA2584338C (en) | 2004-11-04 | 2013-08-06 | Xenoport, Inc. | Gabapentin prodrug sustained release oral dosage forms |
| JP2009505947A (en) | 2005-06-23 | 2009-02-12 | エモリー・ユニバーシティ | Imaging agent |
| KR20070070307A (en) * | 2005-08-24 | 2007-07-04 | 에스에스 세야쿠 가부시키 가이샤 | Sleep-improving pharmaceutical composition |
| US20090069427A1 (en) * | 2006-03-06 | 2009-03-12 | Pfizer Inc. | Alpha-2-delta ligands for non-restorative sleep |
| CA2706575C (en) | 2008-01-25 | 2015-07-14 | Xenoport, Inc. | Enantiomerically resolving acyloxyalkyl thiocarbonates used in synthesizing acyloxyalkyl carbamate prodrugs |
| US7868043B2 (en) | 2008-01-25 | 2011-01-11 | Xenoport, Inc. | Mesophasic forms of (3S)-aminomethyl-5-methyl-hexanoic acid prodrugs and methods of use |
| EP2250148B1 (en) | 2008-01-25 | 2016-08-17 | XenoPort, Inc. | Crystalline form of calcium-salts of (3s)-aminomethyl-5-methyl-hexanoic acids and methods of use |
| US8268887B2 (en) | 2008-10-08 | 2012-09-18 | Feng Xu | Drug conjugates and methods of use thereof |
| EP2509596B1 (en) | 2009-12-08 | 2019-08-28 | Case Western Reserve University | Gamma aminoacids for treating ocular disorders |
| US9066853B2 (en) | 2013-01-15 | 2015-06-30 | Warsaw Orthopedic, Inc. | Clonidine compounds in a biodegradable fiber |
| AU2014209028C1 (en) | 2013-01-28 | 2019-08-29 | Hector L. Lopez | Methods of improving tolerability, pharmacodynamics, and efficacy of b-alanine and use therefor |
| KR20230047198A (en) * | 2016-05-26 | 2023-04-06 | 가부시키가이샤 아미노 압 | Sleep improving agent |
| KR20210013081A (en) | 2018-05-14 | 2021-02-03 | 엑스진 파마슈티컬 인크. | Crystalline form of 1-(acyloxy)-alkyl carbamate drug complex of naproxen and pregabalin |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4087544A (en) | 1974-12-21 | 1978-05-02 | Warner-Lambert Company | Treatment of cranial dysfunctions using novel cyclic amino acids |
| DE2460891C2 (en) | 1974-12-21 | 1982-09-23 | Gödecke AG, 1000 Berlin | 1-aminomethyl-1-cycloalkaneacetic acids and their esters, processes for their preparation and medicaments containing these compounds |
| US5084479A (en) | 1990-01-02 | 1992-01-28 | Warner-Lambert Company | Novel methods for treating neurodegenerative diseases |
| US6197819B1 (en) | 1990-11-27 | 2001-03-06 | Northwestern University | Gamma amino butyric acid analogs and optical isomers |
| US5510381A (en) | 1995-05-15 | 1996-04-23 | Warner-Lambert Company | Method of treatment of mania and bipolar disorder |
| DE19525598C2 (en) * | 1995-07-13 | 1997-09-25 | Max Planck Gesellschaft | sleeping pills |
| KR100487032B1 (en) * | 1996-03-14 | 2005-12-21 | 워너-램버트 캄파니 엘엘씨 | Novel Bridged Cyclic Amino Acids as Pharmaceutical Agents |
| US6372792B1 (en) * | 1996-04-26 | 2002-04-16 | Guy Chouinard | Method for treating anxiety, anxiety disorders and insomnia |
| JP3756761B2 (en) | 1997-10-27 | 2006-03-15 | ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー | Cyclic amino acids and their derivatives useful as pharmaceuticals |
| WO2000002546A2 (en) * | 1998-07-09 | 2000-01-20 | Warner-Lambert Company | Use of caba-analogues for treating insomnia |
| WO2000073300A1 (en) * | 1999-06-02 | 2000-12-07 | Warner-Lambert Company | Amino heterocycles useful as pharmaceutical agents |
| HN2000000224A (en) * | 1999-10-20 | 2001-04-11 | Warner Lambert Co | BICYCLE AMINO ACIDS AS PHARMACEUTICAL AGENTS |
| EP1237847B1 (en) * | 1999-12-08 | 2006-05-17 | Warner-Lambert Company Llc | Method for the stereoselective synthesis of cyclic amino acids |
| GB9930083D0 (en) * | 1999-12-20 | 2000-02-09 | Glaxo Group Ltd | Medicaments |
-
2001
- 2001-05-18 HU HU0300833A patent/HUP0300833A3/en unknown
- 2001-05-18 ES ES01939192T patent/ES2300332T3/en not_active Expired - Lifetime
- 2001-05-18 PL PL35987201A patent/PL359872A1/en not_active Application Discontinuation
- 2001-05-18 CA CA2414008A patent/CA2414008C/en not_active Expired - Fee Related
- 2001-05-18 US US10/297,827 patent/US7141606B2/en not_active Expired - Fee Related
- 2001-05-18 KR KR1020027017609A patent/KR100785182B1/en not_active IP Right Cessation
- 2001-05-18 IL IL15277001A patent/IL152770A0/en unknown
- 2001-05-18 DE DE60133389T patent/DE60133389T2/en not_active Expired - Lifetime
- 2001-05-18 EP EP01939192A patent/EP1296671B1/en not_active Expired - Lifetime
- 2001-05-18 WO PCT/US2001/016343 patent/WO2002000209A2/en active IP Right Grant
- 2001-05-18 MX MXPA02010668A patent/MXPA02010668A/en active IP Right Grant
- 2001-05-18 DK DK01939192T patent/DK1296671T3/en active
- 2001-05-18 AT AT01939192T patent/ATE390133T1/en not_active IP Right Cessation
- 2001-05-18 CN CNB018110487A patent/CN1279900C/en not_active Expired - Fee Related
- 2001-05-18 PT PT01939192T patent/PT1296671E/en unknown
- 2001-05-18 NZ NZ522480A patent/NZ522480A/en unknown
- 2001-05-18 CZ CZ20024110A patent/CZ20024110A3/en unknown
- 2001-05-18 JP JP2002504991A patent/JP3909842B2/en not_active Expired - Fee Related
- 2001-05-18 AU AU2001264736A patent/AU2001264736B2/en not_active Ceased
- 2001-05-18 SK SK1792-2002A patent/SK17922002A3/en not_active Application Discontinuation
- 2001-05-18 BR BR0111913-3A patent/BR0111913A/en not_active Application Discontinuation
- 2001-05-18 AU AU6473601A patent/AU6473601A/en active Pending
- 2001-06-19 TW TW090114841A patent/TWI298020B/en not_active IP Right Cessation
-
2002
- 2002-11-11 IL IL152770A patent/IL152770A/en not_active IP Right Cessation
- 2002-11-19 ZA ZA200209418A patent/ZA200209418B/en unknown
-
2003
- 2003-12-11 HK HK03109027A patent/HK1056681A1/en not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2414008C (en) | Gabapentin analogues for sleep disorders | |
| AU2001264736A1 (en) | Gabapentin analogues for sleep disorders | |
| US4877620A (en) | Ibuprofen-containing medicament | |
| JP3693258B2 (en) | Sedative containing isobutyl GABA or a derivative thereof | |
| IE58314B1 (en) | Pharmaceutical products providing enhanced analgasia | |
| JP3192141B2 (en) | Antidepressant | |
| EP1784177B1 (en) | Formulation for l-tryptophane comprising carbidopa/benserazide | |
| US5519057A (en) | Ibuprofen-containing medicament | |
| US3557292A (en) | Compositions and methods for treating parkinson's disease with combinations of l-3,4-dihydroxyphenylalanine and a hydrazine | |
| JP2004182705A (en) | Preventing and treating composition for development of clinical symptom in disease caused by mitochondria functional abnormality | |
| JPH0684298B2 (en) | Parkinson's disease drug | |
| US4389415A (en) | Method of treating hypertension | |
| JP2017533956A (en) | Combinations for the treatment of pathologies including myalgia | |
| US5948806A (en) | Treatment of Parkinson's disease with (+)2-(ethyl-2,3-dihydrobenzofuranyl)-2-Imidazoline (dexefaroxan or (+) efaroxan) | |
| US4663345A (en) | Etodolac for treatment of gout | |
| KR100379155B1 (en) | New analgesic composition | |
| US4716177A (en) | Tolrestat for inhibition of weight gain | |
| US3686409A (en) | Combination of l-dopa and 2-imino-5-phenyl-4-oxazolidinone used to treat parkinson{40 s disease | |
| AU2007222112A1 (en) | Alpha-2-delta ligands for non-restorative sleep | |
| JPS61200917A (en) | Medicinal composition containing betaxolol and nifedipin | |
| EP0003353A1 (en) | A pharmaceutical composition for oral administration for treating hypertension | |
| JP2002520278A (en) | Treatment of renal colic with GABA analogs | |
| RU98114485A (en) | FIRE-REDUCING COMPOSITION AND METHOD OF TREATMENT AND PREVENTION OF HYPERTHERMIA IN HUMAN |